Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotechnology Business
Roche Considering Legal Options In Patent Litigation Case
November 9th, 2007
Roche announced that a jury in the U.S. District Court in Massachusetts found in favor of Amgen in the patent infringement dispute relating to the Roche erythropoiesis-stimulating agent, MIRCERA(R) . Roche is currently evaluating its legal options, including the possibility of an appeal. Roche maintains its position that all of Amgen's patents for epoetin asserted against Roche are invalid and not infringed, and believes the facts and the law support that position. "The jury's verdict is disappointing because it is a loss for U.S. patients with chronic kidney disease who are being deprived of the opportunity to benefit from options in the management...
Source: Biotech Law Weekly (2007-11-09)
|
